NCT02501577 (supraview) is a NA clinical trial of SAD 1 in Intubation; Difficult, sponsored by University of Regensburg.

Who is sponsoring NCT02501577?

NCT02501577 is sponsored by University of Regensburg.

What drugs are being tested in NCT02501577?

Interventions in NCT02501577: SAD 1, SAD 2.

What condition does NCT02501577 study?

NCT02501577 studies Intubation; Difficult.

Is NCT02501577 still recruiting?

NCT02501577 is currently status unknown. Last updated 16 July 2015.

Last reviewed 2015-07-16 · How we verify

NCT02501577: supraview

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Various Supraglottic Airway Devices for Fiberoptical Guided Tracheal Intubation

Status unknown NA Last updated 16 July 2015

What this trial tests

NA trial testing SAD 1 in Intubation; Difficult in 30 participants. Status unknown.

Timeline

1 March 2015

Primary endpoint
1 October 2015

1 October 2015

Quick facts

Lead sponsor	University of Regensburg
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	basic science
Enrollment	30
Start date	1 March 2015
Primary completion	1 October 2015
Estimated completion	1 October 2015
Sites	1 location across Germany

Drugs / interventions tested

SAD 1
SAD 2

Conditions studied

Intubation; Difficult — all drugs for Intubation; Difficult →

Sponsor

University of Regensburg

Who can join

Adults 18 to 80, any sex, with Intubation; Difficult. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Visibility of vocal cords
Time frame: intraoperative

Sponsor's own description

Placement of a supraglottic airway device Fiberoptical verification of pharyngeal position

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Regensburg trials

Trials by the same sponsor.

NCT07444242 — Accelerated Treatment of Depressive Patients With tDCS · NA · not yet recruiting
NCT06766214 — Attexis and tDCS for the Treatment of ADHD · NA · completed
NCT06689592 — Mobile Transcranial Magnetic Stimulation · NA · completed
NCT06520865 — TIDE Project: Biomarker Discovery for Chronic Tinnitus Diagnosis · completed
NCT06212895 — Expectations of Patients Regarding Exercise in an Outpatient Clinic · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02501577 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Regensburg
Last refreshed: 16 July 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02501577.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing